血清胸苷激酶1（STK1）在预测T4期肺鳞状细胞癌免疫治疗预后中的关键作用。

The critical role of serum thymidine kinase 1(STK1) in predicting prognosis for immunotherapy in T4 stage lung squamous cell carcinoma.

作者信息

Pan Jinmiao, Liu Haizhou, Li Shirong, Wei Wene, Mai Jinling, Bian Yingzhen, Ning Shufang, Li Jilin, Zhang Litu

机构信息

Department of Research, Guangxi Medical University Cancer Hospital, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

Department of Research, Guangxi Cancer Molecular Medicine Engineering Research Center, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

出版信息

Heliyon. 2023 Feb 27;9(3):e14129. doi: 10.1016/j.heliyon.2023.e14129. eCollection 2023 Mar.

DOI:10.1016/j.heliyon.2023.e14129

PMID:36938402

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10018465/

Abstract

PURPOSE

The role of serum thymidine kinase 1 (STK1) in predicting the prognosis of T4-stage lung squamous cell carcinoma (LUSC) with immunotherapy is the focus of our work.

METHODS

A total of 180 LUSC patients were enrolled. In this study, according to the T stage, the patients were divided into two groups: the T1-T2 stage and the T3-T4 stage. Receiver operating characteristic (ROC) curves were used to determine the best cutoff value for predicting overall survival (OS) outcomes. The next step is to use this cutoff value to introduce univariate and multivariate Cox regression models to screen the prognostic factors in different T stages of LUSC. The association of STK1 with other clinicopathological factors was also determined. Finally, to further explore the link between STK1 and the staging of LUSC patients, we have further divided the staging into T1-3 and T4 stages. We identified factors influencing the prognosis of patients who received immunotherapy in T4 stage LUSC.

RESULTS

First, we determined that the optimal cutoff for STK1 for predicting OS outcome was 1.165 pmol/L. Correlation analysis revealed that STK1 was over-expressed in LUSC patients at the T3-4 stage. Univariate and multivariate analysis showed that immunotherapy was an independent prognostic factor in patients with T4 stage LUSC. In the group of patients who received immunotherapy or not, the STK1 expression level was found to be an independent prognostic factor in T4 LUSC patients receiving PD-1/PD-L1 inhibitor treatment; patients with high levels of STK1 had an increased risk of death (95%CI = 1.028-2.04).

CONCLUSION

STK1 is associated with a higher T stage and may be an effective prognostic marker for advanced LUSC immunotherapy patients.

摘要

目的

血清胸苷激酶1（STK1）在预测接受免疫治疗的T4期肺鳞状细胞癌（LUSC）预后中的作用是我们研究的重点。

方法

共纳入180例LUSC患者。在本研究中，根据T分期将患者分为两组：T1-T2期和T3-T4期。采用受试者工作特征（ROC）曲线确定预测总生存期（OS）结果的最佳截断值。下一步是使用该截断值引入单因素和多因素Cox回归模型，以筛选LUSC不同T分期的预后因素。还确定了STK1与其他临床病理因素的相关性。最后，为进一步探讨STK1与LUSC患者分期之间的联系，我们将分期进一步分为T1-3期和T4期。我们确定了影响T4期LUSC患者接受免疫治疗预后的因素。

结果

首先，我们确定STK1预测OS结果的最佳截断值为1.165 pmol/L。相关性分析显示，STK1在T3-4期LUSC患者中过表达。单因素和多因素分析表明，免疫治疗是T4期LUSC患者的独立预后因素。在接受或未接受免疫治疗的患者组中，发现STK1表达水平是接受PD-1/PD-L1抑制剂治疗的T4期LUSC患者的独立预后因素；STK1水平高的患者死亡风险增加（95%CI = 1.028-2.04）。